Lyell Immunopharma, Inc.

The company was founded by cell-therapy researchers and physicians including Rick Klausner, Crystal Mackall, and Stanley Riddell. Its initial research focused on overcoming limitations of adoptive cell therapy, including T-cell exhaustion and inadequate persistence in solid tumors.

In June 2021, Lyell completed its initial public offering on Nasdaq under the symbol LYEL, The company emerged from stealth mode with substantial private funding to solve the core biological barriers limiting the efficacy of adoptive cell therapies against solid tumors raising approximately $425 million before underwriting discounts and commissions in its initial public offering (IPO).

In October 2024, Lyell completed its acquisition of ImmPACT Bio. The transaction added ImmPACT Bio's dual-targeting CD19/CD20 CAR T-cell program, subsequently identified as rondecabtagene autoleucel (ronde-cel), also known as LYL314.